Revealing the key player in oral submucous fibrosis: could COMP be the solution?
en-GBde-DEes-ESfr-FR

Revealing the key player in oral submucous fibrosis: could COMP be the solution?

28/04/2025 TranSpread

Oral submucous fibrosis (OSF) is a chronic condition commonly affecting the oral mucosa, causing an excessive buildup of collagen that disrupts tissue function and increases the risk of cancer. While the involvement of collagen in OSF is well-known, the exact molecular mechanisms behind its abnormal deposition have remained elusive. Though other extracellular matrix proteins have been linked to fibrosis, the role of cartilage oligomeric matrix protein (COMP) in this process was not fully understood until now. Given the complex nature of OSF, this study highlights the need for further research to clarify COMP's role and its potential as a therapeutic target.

Published (DOI: 10.1038/s41368-025-00355-x) in the International Journal of Oral Science on March 27, 2025, this groundbreaking study from researchers at Xiangya Hospital, Central South University, delves into the molecular underpinnings of OSF. By combining RNA sequencing, immunofluorescence assays, and animal models, the team identified COMP as a key driver of abnormal collagen I deposition, shedding new light on the disease's progression and offering hope for more effective treatments.

The study explores the dynamic process of collagen deposition in OSF, uncovering a clear pattern: collagen I initially accumulates in the lamina propria and then progresses deeper into the submucosa as the disease advances. Through RNA sequencing, the researchers discovered that COMP expression is markedly upregulated during this progression. By using Comp-/- mice, they showed that the absence of COMP significantly reduced the collagen I buildup induced by arecoline, a compound known to trigger OSF. Furthermore, the study reveals that COMP interacts with collagen XIV, a member of the FACIT family, which is integral to the collagen network. This interaction is key to the abnormal collagen deposition seen in OSF, suggesting that targeting COMP could be an effective strategy to prevent or reverse this harmful process.

Dr. Feng Guo, an expert in oral regenerative medicine, emphasizes, "This discovery of COMP’s role in OSF opens new doors for targeted therapies. By intervening in the interactions between COMP and collagen XIV, we may be able to halt or even reverse the pathological collagen accumulation, providing a promising new avenue for treating OSF and improving patient quality of life."

This research has profound implications for OSF treatment. By targeting COMP and its interaction with collagen XIV, new therapies could be developed to curb excessive collagen buildup, potentially preventing the disease from progressing further. Beyond OSF, the findings also hold promise for treating other fibrotic conditions, such as scleroderma and pulmonary fibrosis, where collagen deposition plays a central role. Ultimately, this study brings us one step closer to more effective, targeted treatments for a range of collagen-related diseases.

###

References

DOI

10.1038/s41368-025-00355-x

Original Source URL

https://doi.org/10.1038/s41368-025-00355-x

Funding Information

This work was supported by the National Natural Science Foundation of China grant (81974150).

About International Journal of Oral Science

International Journal of Oral Science (ISSN 1674-2818) was founded in 2009 and aims to publish all aspects of oral science and interdisciplinary fields, including fundamental, applied and clinical research. Covered areas include oral microbiology, oral and maxillofacial oncology, cariology, oral inflammation and infection, dental stem cells and regenerative medicine, craniofacial surgery, dental materials, oral biomechanics, oral, dental and maxillofacial genetic and developmental diseases.

Paper title: Abnormal collagen deposition mediated by cartilage oligomeric matrix protein in the pathogenesis of oral submucous fibrosis
Attached files
  • Pathological characteristics of abnormal collagen I and collagen III accumulation during OSF progression. a Distribution and expression of collagen I in the lamina propria and submucosa. b Immunofluorescence assay of collagen I in the lamina propria and submucosa. c Distribution and expression of collagen III in the lamina propria and submucosa. d Immunofluorescence assay of collagen III in the lamina propria and submucosa. scale bar = 50 μm, n = 28, Data are presented as mean ± SD, *P < 0.05, ***P < 0.001, ****P < 0.000 1.
28/04/2025 TranSpread
Regions: North America, United States, Asia, China
Keywords: Health, Medical, Business, Medical & pharmaceutical

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Testimonials

For well over a decade, in my capacity as a researcher, broadcaster, and producer, I have relied heavily on Alphagalileo.
All of my work trips have been planned around stories that I've found on this site.
The under embargo section allows us to plan ahead and the news releases enable us to find key experts.
Going through the tailored daily updates is the best way to start the day. It's such a critical service for me and many of my colleagues.
Koula Bouloukos, Senior manager, Editorial & Production Underknown
We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet

We Work Closely With...


  • e
  • The Research Council of Norway
  • SciDevNet
  • Swiss National Science Foundation
  • iesResearch
Copyright 2025 by AlphaGalileo Terms Of Use Privacy Statement